Commentary|Articles|September 11, 2025

Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting

Author(s)Jax DiEugenio
Fact checked by: Ashling Wahner

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

The 22nd International Myeloma Society (IMS) Annual Meeting, taking place September 17–20, 2025, in Toronto, Canada, will highlight key advances across multiple myeloma research, including progress in precursor disease profiling and management, risk-adapted management strategies, immunotherapy optimization, and strategies for patients experiencing early relapse.1 Additional sessions will spotlight late-breaking data on the predictive role of minimal residual disease (MRD), the efficacy of novel bispecific antibody combinations, and approaches for high-risk disease.

Related to this article